Evidence map›Paper›PMID 21980470›Full record

ArticlePloS one2011

Identification of a variable number of tandem repeats polymorphism and characterization of LEF-1 response elements in the promoter of the IDO1 gene.

Marion Soichot, Benjamin Hennart, Alaa Al Saabi, Audrey Leloire, Philippe Froguel, Claire Levy-Marchal, Odile Poulain-Godefroy, Delphine Allorge

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Prognostic value of the PrPOncoimmunology · 2021
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Frontiers in immunology · 2018
    Article
  11. Article
  12. Review
  13. Characterization of theOncoimmunology · 2015
    Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Marion SoichotEquipe d'Accueil 4483, Faculté de Médecine de Lille, UDSL, Université Lille-Nord de France, Lille, France.
Benjamin Hennart
Alaa Al Saabi
Audrey Leloire
Philippe Froguel
Claire Levy-Marchal
Odile Poulain-Godefroy
Delphine Allorge
Université Lille Nord de France · FRCentre National de la Recherche Scientifique · FRInserm · FRInstitut Pasteur de Lille · FR

Funding

Medical Research Council G0700342
6 · The paper itself

Abstract

backgroundIndoleamine 2,3-dioxygenase (IDO) catalyzes the first and rate-limiting step of the kynurenine pathway that is an important component of immunomodulatory and neuromodulatory processes. The IDO1 gene is highly inducible by IFN-γ and TNF-α through interaction with cis-acting regulatory elements of the promoter region. Accordingly, functional polymorphisms in the IDO1 promoter could partly explain the interindividual variability in IDO expression that has been previously documented. METHODOLOGY/PRINCIPAL

findingsA PCR-sequencing strategy, applied to DNA samples from healthy Caucasians, allowed us to identify a VNTR polymorphism in the IDO1 promoter, which correlates significantly with serum tryptophan concentration, controlled partially by IDO activity, in female subjects, but not in males. Although this VNTR does not appear to affect basal or cytokine-induced promoter activity in gene reporter assays, it contains novel cis-acting elements. Three putative LEF-1 binding sites, one being located within the VNTR repeat motif, were predicted in silico and confirmed by chromatin immunoprecipitation. Overexpression of LEF-1 in luciferase assays confirmed an interaction between LEF-1 and the predicted transcription factor binding sites, and modification of the LEF-1 core sequence within the VNTR repeat motif, by site-directed mutagenesis, resulted in an increase in promoter activity. CONCLUSIONS/SIGNIFICANCE: The identification of a VNTR in the IDO1 promoter revealed a cis-acting element interacting with the most downstream factor of the Wnt signaling pathway, suggesting novel mechanisms of regulation of IDO1 expression. These data offer new insights, and suggest further studies, into the role of IDO in various pathological conditions, particularly in cancer where IDO and the Wnt pathway are strongly dysregulated.

Indexed as

Base SequenceDNAExonsFemaleGene Expression Regulation, EnzymologicHumansIndoleamine-Pyrrole 2,3,-DioxygenaseIntronsLymphoid Enhancer-Binding Factor 1MaleMinisatellite RepeatsMolecular Sequence DataPolymorphism, GeneticResponse ElementsTranscription, GeneticTryptophanDNAIndoleamine-Pyrrole 2,3,-DioxygenaseLEF1 protein, humanLymphoid Enhancer-Binding Factor 1Tryptophan

Identifiers

PMID21980470
PMCPMC3181322
OpenAlexW1967857971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.